Two major peaks were evident when HL-60 cells were present in culture (positions 2-3;Figure 6A), whereas only one peak appeared in the absence of cells (position 5;Figure 6B). formation, and leukocyte adhesion via the selectins. == Introduction == The binding of adhesion molecules belonging to the selectin family to carbohydrate ligands facilitates the adhesion of blood leukocytes to activated endothelial cells, platelets, and other leukocytes in Cetrorelix Acetate the human vasculature.1,2Such molecular interactions play an important role in regulating leukocyte recruitment at sites of inflammation, cancer metastasis, and various cardiovascular disorders.3Whereas numerous glycoproteins and glycolipids participate in selectin-mediated cell adhesion, interactions with carbohydrate epitopes expressed on the leukocyte glycoprotein P-selectin glycoprotein ligand-1 (PSGL-1, CD162) are particularly important because this ligand binds all 3 members of the selectin family (E-, P-, and L-selectin) with high affinity and under fluid flow conditions. Structural analysis of the glycans of PSGL-1 expressed on human promyelocytic leukemia HL-60 cells reveals that PSGL-1 is predominantly composed of core-2 based O-linked glycans.4,5The prototypic selectin-binding carbohydrate structure sialyl Lewis-X (NeuAc2,3Gal1,4(Fuc1,3)GlcNAc-, sLeX;Figure 1A) is expressed on 2% to 14% of these O-glycans. == Figure 1. == Glycan epitopes and monosaccharide analogs.(A) Putative structure of selectin-binding glycan located at the N-terminus of PSGL-1. This glycan has a terminal tetrasaccharide sLeXepitope and binding sites for DSA and AAL lectins. Neuraminidase cleaves sialic acid (NeuAc) residues to expose the terminal trisaccharide Lewis-X (LeX) epitope. Metabolic inhibition of these glycan structures may reduce leukocyte selectin-binding function. (B) Structure of per-acetylated compounds GalNAc, 4F-GalNAc, 4F-GlcNAc, and [14C]4F-GalNAc. There is active interest in developing antagonists that control/block selectin-mediated cell adhesion using either competitive inhibitors or metabolic inhibitors. Competitive inhibitors attempt to block cell adhesion by regulating the ligand-binding epitope of either the selectin or its primary counter-receptor PSGL-1. Antagonists used for such inhibition include the tetrasaccharide sLeXand its glycomimetics,6humanized antibodies directed against selectins,79and soluble recombinant PSGL-1-Ig fusion protein.10Only limited clinical success has been reported with these molecules, thus far. 11Although the use of competitive inhibitors is conceptually straightforward, in practice this is complicated by the overlapping functional redundancies among the members of the selectin family and their carbohydrate ligands, the multiple roles of selectins in both ligand binding and signaling, and the limited half-life in circulation of some classes of inhibitors. The use of metabolic inhibitors is more recent and less well developed. These are mostly designed based on the growing knowledge of cellular glycosylation reactions and pathways. This approach uses small molecules that penetrate the cell to divert/block metabolic pathways that normally lead to the formation of selectin-binding carbohydrate epitopes. This strategy targets a group of related cellular reactions as opposed to a single pathway. Preliminary success has been noted using this approach. First, surrogate acceptors or decoys that act as unnatural substrates for glycosyltransferases have been introduced into cells. Glycosyltransferases act on such artificial substrates. This results in incomplete glycosylation of the natural glycoconjugates. Although an early approach showed that aryl-N-acetyl–galactosaminides (benzl, phenyl, PSMA617 TFA p-nitrophenyl–GalNAc) added to cell culture media can alter glycans on mucinous glycoproteins, these reagents were applied at high concentrations (1-7.5mM).12Later, it was demonstrated that per-acetylated forms of Gal1,4GlcNAc–O-napthalenemethanol and GlcNAc1,3Gal–O-Gal1,4GlcNAc–O-napthalenemethanol at 50M can act as decoys/primers that block selectin-ligand formation.1316Second, glycosyltransferase inhibitors are also in development based on the structure of the sugar-nucleotide transition-state analogs17,18and high throughput screens,19although testing of these reagents has largely been performed in cell-free enzymatic assays. Third, per-acetylated, modified monosaccharides have been applied to cells as these may compete with the natural monosaccharides. Here, unnatural monosaccharides are incorporated into cellular glycoconjugates.2024Although analogs of galactose, GlcNAc, GalNAc, and mannose have been synthesized, only limited studies have been conducted in cellular assays.25274F-GlcNAc is an example of this class of inhibitors. This molecule reduces selectin-mediated cutaneous lymphocyte-associated antigen (CLA+) T-cell adhesion in vitro,28and in in vivo models of skin inflammation.2931 Because O-linked glycans linked to PSGL-1 and other glycoproteins participate as important selectin ligands and because the attachment of GalNAc to serine/threonine residues on the peptide backbone is critical for the initiation of O-glycan assembly, we tested the hypothesis that modified monosaccharides based on GalNAc may be used to disrupt/alter the pattern PSMA617 TFA of O-linked glycosylation. This can result PSMA617 TFA in reduced selectin binding function. In this regard, unlike GlcNAc, which plays a major role in modifying both N- and O-linked glycans,.